ArticleCureus2024
A Case of Ramucirumab for Radiation Necrosis Following Stereotactic Radiotherapy for Brain Metastases From Lung Cancer.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well known that bevacizumab is effective against radiation necrosis in the brain (hereafter referred to as brain necrosis). Herein, we report a case of brain necrosis in a patient treated with a regimen that included ramucirumab, an anti-vascular endothelial growth factor (VEGF) inhibitor. A woman in her 40s presented with five brain metastases from lung adenocarcinoma at the initial diagnosis. Each metastasis was treated with stereotactic radiotherapy. Subsequent magnetic resonance imaging showed increased oedema surrounding the lesion in the left frontal lobe, leading to a diagnosis of radiation-induced brain necrosis. Docetaxel + ramucirumab was chosen for third-line chemotherapy. During treatment, perioperative brain necrotic oedema diminished. Furthermore, anti-VEGF inhibitor regimens should be considered for reducing oedema associated with radiation necrosis of the brain, as they can be utilized alongside chemotherapy for the primary tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.